I 

116TH CONGRESS 

1ST SESSION H. R. 4764 

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and 

for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

OCTOBER 18, 2019 

Ms. MATSUI (for herself, Mr. BILIRAKIS, and Ms. PINGREE) introduced the 

following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To reauthorize the Stem Cell Therapeutic and Research Act 

of 2005, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Timely ReAuthoriza5 tion of Necessary Stem-cell Programs Lends Access to 

6 Needed Therapies Act of 2019’’ or the ‘‘TRANSPLANT 

7 Act of 2019’’. 

2 

•HR 4764 IH

1 SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL 

2 TRANSPLANTATION PROGRAM. 

3 (a) ADVISORY COUNCIL MEETINGS.—Subsection (a) 

4 of section 379 of the Public Health Service Act (42 U.S.C. 

5 274k) is amended by adding at the end the following new 

6 paragraph: 

7 ‘‘(7) The Secretary shall convene the Advisory 

8 Council at least two times each calendar year.’’. 

9 (b) INCREASING COLLECTION.— 

10 (1) TECHNICAL CLARIFICATION.—Effective as 

11 if included in the enactment of Public Law 114–104 

12 (the Stem Cell Therapeutic and Research Reauthor13 ization Act of 2015), the amendment to section 

14 379(d)(2)(B) of the Public Health Service Act (42 

15 U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public 

16 Law 114–104 is amended by inserting ‘‘goal of in17 creasing collections of high quality’’ before ‘‘cord 

18 blood units,’’. 

19 (2) ELIMINATING DEADWOOD.—Subparagraph 

20 (B) of section 379(d)(2) of the Public Health Serv21 ice Act (42 U.S.C. 274k(d)(2)) is amended by strik22 ing the second and third sentences in such subpara23 graph. 

24 (c) PERIODIC REVIEW OF STATE OF SCIENCE.—Sec25 tion 379 of the Public Health Service Act (42 U.S.C. 

3 

•HR 4764 IH

1 274k) is amended by adding at the end the following new 

2 subsection: 

3 ‘‘(o) PERIODIC REVIEW OF STATE OF SCIENCE.— 

4 ‘‘(1) REVIEW.—Not less than every two years, 

5 the Secretary, in consultation with the Director of 

6 the National Institutes of Health, the Commissioner 

7 of Food and Drugs, the Administrator of the Health 

8 Resources and Services Administration, the Advisory 

9 Council, and other stakeholders, where appropriate 

10 given relevant expertise, shall conduct a review of 

11 the state of the science of using adult stem cells and 

12 birthing tissues to develop new types of therapies for 

13 patients, for the purpose of considering the potential 

14 inclusion of such new types of therapies in the Pro15 gram. 

16 ‘‘(2) RECOMMENDATIONS.—Not later than 

17 June 30, 2024, the Secretary shall— 

18 ‘‘(A) complete the second review required 

19 by paragraph (1); and 

20 ‘‘(B) informed by such review, submit to 

21 the Committee on Health, Education, Labor, 

22 and Pensions of the Senate and the Committee 

23 on Energy and Commerce of the House of Rep24 resentatives recommendations on the approVerDate Sep 11 2014 20:49 Oct 28, 2019 Jkt 099200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H4764.IH H4764
4 

•HR 4764 IH

1 priateness of the inclusion of new types of 

2 therapies in the Program.’’. 

3 (d) AUTHORIZATION OF APPROPRIATIONS.—Section 

4 379B of the Public Health Service Act (42 U.S.C. 274m) 

5 is amended by striking ‘‘$33,000,000 for fiscal year 2015 

6 and $30,000,000 for each of fiscal years 2016 through 

7 2020’’ and inserting ‘‘$30,000,000 for each of fiscal years 

8 2021 through 2025’’. 

9 SEC. 3. CORD BLOOD INVENTORY. 

10 Subsection (g) of section 2 of the Stem Cell Thera11 peutic and Research Act of 2005 (42 U.S.C. 274k note) 

12 is amended to read as follows: 

13 ‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—To 

14 carry out this section, there is authorized to be appro15 priated $23,000,000 for each of fiscal years 2021 through 

16 2025.’’. 

Æ